Ned Pagliarulo is the Lead Editor at BioPharmaDive, where he covers the latest developments in the biopharmaceutical industry. With a focus on providing in-depth analysis and breaking news, Ned's articles explore topics such as drug approvals, mergers and acquisitions, clinical trials, and advancements in gene editing and therapy.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Ned Pagliarulo's coverage predominantly focuses on the healthcare and pharmaceutical industries, with a substantial emphasis on industry-specific announcements and data citations. He would likely be interested in receiving pitches focused on breaking news related to pharmaceutical companies, drug development updates, FDA approvals, and biotech company developments.
Given Ned’s focus on press releases and data citations, he may be particularly receptive to pitches that provide exclusive access to newly released data or insights into industry trends. Experts who can offer unique perspectives based on their experience within the pharmaceutical or biotechnology sectors are also likely to capture his attention.
Since Ned does not have a specific geographic focus mentioned, it is important for potential sources to ensure that their pitches are relevant from a global perspective rather than being limited by location-specific details.
This information evolves through artificial intelligence and human feedback. Improve this profile .
The combined company, which will pair Chroma's epigenetic editing with Nvelop's non-viral particles, has raised $75 million from a syndicate of nearly 20 investors.
The biotech will cut 180 positions, or about two-thirds of its workforce, and discontinue development of its lead drug candidate reni-cel.
The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target of AbbVie’s blockbuster injection Skyrizi.
By: Ned Pagliarulo
The $16.5 billion take-private deal can now be completed, and along with it Novo Nordisk’s related acquisition of three Catalent drug manufacturing plants.
The biotech company will meet with regulators to discuss Phase 2 biomarker data that sent its shares climbing by more than 20% Monday.
Bruce Cozadd, who co-founded the company two decades ago, will step down once a successor is found. Jazz aims to complete its search within one year.
The company forecast revenue next year will grow slightly versus this year, when excluding certain factors. “We believe we are entering a phase of revenue stability,” its CFO said.
Bumpus replaced agency veteran Janet Woodcock as principal deputy commissioner in February 2024. She was previously the agency's chief scientist.
The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.
(833) 317-6278 
